|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0039286,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0227843,
umls-concept:C0439234,
umls-concept:C0878174,
umls-concept:C1274040,
umls-concept:C1363878,
umls-concept:C1522673,
umls-concept:C1710684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-1-20
|
|
pubmed:abstractText |
Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years. Anastrozole, a third-generation aromatase inhibitor, with superior efficacy to tamoxifen, may also offer tolerability benefits in terms of effects on the endometrium.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0268-1161
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
545-53
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:16210385-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16210385-Breast Neoplasms,
pubmed-meshheading:16210385-Chemotherapy, Adjuvant,
pubmed-meshheading:16210385-Endometrial Neoplasms,
pubmed-meshheading:16210385-Endometrium,
pubmed-meshheading:16210385-Female,
pubmed-meshheading:16210385-Humans,
pubmed-meshheading:16210385-Middle Aged,
pubmed-meshheading:16210385-Nitriles,
pubmed-meshheading:16210385-Polyps,
pubmed-meshheading:16210385-Risk Factors,
pubmed-meshheading:16210385-Tamoxifen,
pubmed-meshheading:16210385-Triazoles
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynaecology, St James' University Hospital, Leeds LS9 7TF, UK.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
